How to appeal an Aetna amyloidosis (cardiac attr + al) denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal an Aetna amyloidosis (cardiac attr + al) denial, file an internal appeal within 180 days of the date on the denial letter through Aetna's member or provider portal, under ACA §2719 + ERISA §503. Aetna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.
What Aetna's policy requires for amyloidosis (cardiac attr + al)
Cited policy: Aetna CPB on Attruby (Acoramidis) for ATTR Cardiomyopathy
Adult with confirmed ATTR-CM (wild-type or hereditary) per non-invasive Gillmore algorithm OR biopsy + mass-spec. NYHA I-III. NT-proBNP >=300 pg/mL. eGFR >=30. Not concurrent with tafamidis or other TTR stabilizer or TTR silencer (vutrisiran/patisiran/eplontersen). Cardiologist Rx with amyloidosis center involvement.
How Aetna denies amyloidosis (cardiac attr + al) — and how to counter it
Where Aetna pushes back: 1) Try tafamidis first (step therapy); 2) Cross-trial inferiority asserted vs tafamidis; 3) ATTRibute-CM win-ratio 'inadequate' as endpoint; 4) Limit to ATTRv only.
Counter-arguments that hold up: FDA approved acoramidis Nov 22, 2024 as first-line monotherapy — NO mandated step-through tafamidis. ATTRibute-CM (Gillmore NEJM 2024) was placebo-controlled, not head-to-head — cross-trial inferiority claim methodologically unsound. Win-ratio 1.8 hierarchical endpoint (mortality + CV hospitalization + NT-proBNP + 6MWD) is FDA-accepted; primary p-value met. Acoramidis is near-complete (>=90%) TTR stabilizer per FDA label — the first such designation. Both ATTRwt and ATTRv labeled. Mortality 19% vs 26% (HR 0.72); CV hospitalization rate 0.29 vs 0.60/yr.
What Aetna typically denies for amyloidosis (cardiac attr + al)
Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For amyloidosis (cardiac attr + al), expect:
- UM-2575 medical necessity denials
- Prior auth absent
- Step therapy on specialty drugs
- Out-of-network ER reduction
Treatments most often denied in this category
These are the amyloidosis (cardiac attr + al) treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Vyndaqel / Vyndamax (tafamidis)
- Attruby (acoramidis)
- Amvuttra (vutrisiran) ATTR-CM
- Onpattro (patisiran)
- Wainua (eplontersen)
- D-VCd for AL
How to submit the appeal to Aetna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
- File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal an Aetna amyloidosis (cardiac attr + al) denial?
Aetna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit an Aetna appeal?
Members can submit through the Aetna member portal at https://www.aetna.com. Providers should use the provider portal at https://www.aetnaprovider.com. Faxed and mailed appeals are accepted but take longer.
What denials does Aetna most often issue for amyloidosis (cardiac attr + al)?
For amyloidosis (cardiac attr + al), Aetna most often denies on: 1) Try tafamidis first (step therapy); 2) Cross-trial inferiority asserted vs tafamidis; 3) ATTRibute-CM win-ratio 'inadequate' as endpoint; 4) Limit to ATTRv only. The strongest counters: FDA approved acoramidis Nov 22, 2024 as first-line monotherapy — NO mandated step-through tafamidis. ATTRibute-CM (Gillmore NEJM 2024) was placebo-controlled, not head-to-head — cross-trial inferiority claim methodologically unsound. Win-ratio 1.8 hierarchical endpoint (mortality + CV hospitalization + NT-proBNP + 6MWD) is FDA-accepted; primary p-value met. Acoramidis is near-complete (>=90%) TTR stabilizer per FDA label — the first such designation. Both ATTRwt and ATTRv labeled. Mortality 19% vs 26% (HR 0.72); CV hospitalization rate 0.29 vs 0.60/yr.
What if Aetna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Amyloidosis (cardiac ATTR + AL) appeal
Upload your Aetna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com